Compounds > guanfacine
Page last updated: 2024-10-28

guanfacine and Cognition Disorders

guanfacine has been researched along with Cognition Disorders in 11 studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research Excerpts

ExcerptRelevanceReference
"Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate."6.70Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001)
"Guanfacine was associated with improved WM performance in the MTBI but not the HC group."2.76Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response. ( Ferrell, RB; Flashman, LA; Grove, MR; McAllister, TW; McDonald, BC; Saykin, AJ; Tosteson, TD; Yanofsky, NN, 2011)
"Guanfacine has demonstrated efficacy in reversing working memory deficits in non-human primate."2.70Guanfacine treatment of cognitive impairment in schizophrenia. ( Adler, DN; Davis, KL; Friedman, JI; Harvey, PD; Kemether, E; Parrella, M; Temporini, HD; White, L, 2001)
"Guanfacine was well tolerated, and did not lead to significant changes in blood pressure or heart rate."1.32Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. ( Kem, DL; McDougle, CJ; Posey, DJ; Puntney, JI; Sasher, TM, 2004)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's4 (36.36)29.6817
2010's5 (45.45)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Arnsten, AFT1
Kauser, H1
Sahu, S1
Kumar, S1
Panjwani, U1
Freeman, ZT1
Rice, KA1
Soto, PL1
Pate, KA1
Weed, MR1
Ator, NA1
DeLeon, IG1
Wong, DF1
Zhou, Y1
Mankowski, JL1
Zink, MC1
Adams, RJ1
Hutchinson, EK1
McAllister, TW1
McDonald, BC1
Flashman, LA1
Ferrell, RB1
Tosteson, TD1
Yanofsky, NN1
Grove, MR1
Saykin, AJ1
Arnsten, AF2
Jin, LE1
Chapman, SB1
Cotman, CW1
Fillit, HM1
Gallagher, M1
van Dyck, CH1
Friedman, JI2
Stewart, DG1
Gorman, JM1
Posey, DJ1
Puntney, JI1
Sasher, TM1
Kem, DL1
McDougle, CJ1
McClure, MM1
Barch, DM1
Romero, MJ1
Minzenberg, MJ1
Triebwasser, J1
Harvey, PD2
Siever, LJ1
Steere, JC1
Hunt, RD1
Adler, DN1
Temporini, HD1
Kemether, E1
White, L1
Parrella, M1
Davis, KL1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Guanfacine for PONV and Pain After Sinus Surgery[NCT02882854]84 participants (Actual)Interventional2016-11-30Completed
A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646]Phase 448 participants (Actual)Interventional2018-09-26Active, not recruiting
Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum[NCT02524899]Phase 245 participants (Actual)Interventional2014-01-31Completed
Pharmacology of Cognition in Schizotypal Personality Disorder: Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder[NCT00353379]Phase 429 participants (Actual)Interventional1995-09-30Terminated (stopped due to low enrollment)
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885]16 participants (Actual)Interventional2008-08-31Completed
A Single-blind, Randomised, Sham Controlled, Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of BGX-3006 (tPCS) on Paediatric ADHD Participants.[NCT02323633]Phase 248 participants (Anticipated)Interventional2015-01-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

PACU Length of Stay in Minutes

(NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes

Interventionminutes (Median)
Guanfacine128
Placebo110

Postoperative Nausea Assessment Using 11-point Nausea Scale (nVRS)

PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea. (NCT02882854)
Timeframe: 24 hours post op

Interventionscore on a scale (Median)
Guanfacine0.00
Placebo0.00

Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)

Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 24 hours postop

Interventionscore on a scale (Median)
Guanfacine3
Placebo2

Total Narcotic Requirement in PACU

Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay (NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes

Interventionmorphine equivalents (Median)
Guanfacine8.75
Placebo7.50

Maximum Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS)

Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 15, 30, 60 minutes after arriving in PACU

InterventionParticipants (Count of Participants)
15 minutes after PACU admission7248297715 minutes after PACU admission7248297830 minutes after PACU admission7248297730 minutes after PACU admission7248297860 minutes after PACU admission7248297760 minutes after PACU admission72482978
Mild (Pain nVRS 1-5)Moderate/Severe (Pain nVRS 6-10)None (Pain nVRS 0)
Guanfacine31
Placebo24
Guanfacine0
Placebo5
Guanfacine8
Placebo10
Guanfacine18
Placebo20
Guanfacine7
Placebo6
Guanfacine14
Placebo14
Guanfacine12
Placebo16
Guanfacine6
Placebo13
Guanfacine21
Placebo12

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Inferior Parietal Lobule

"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Interventionpercent change in saline signal (Mean)
Guanfacine-0.17
Placebo-0.094

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Middle Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Interventionpercent change in saline signal (Mean)
Guanfacine-0.1
Placebo0.052

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Superior Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Interventionpercent change in saline signal (Mean)
Guanfacine-0.134
Placebo-0.086

Reviews

5 reviews available for guanfacine and Cognition Disorders

ArticleYear
Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.
    Neurobiology of learning and memory, 2020, Volume: 176

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Attention Deficit Disorder with Hyperactivity; Cognit

2020
Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
    The Yale journal of biology and medicine, 2012, Volume: 85, Issue:1

    Topics: Animals; Cognition Disorders; Drug Discovery; Guanfacine; History, 20th Century; Humans; Memory, Sho

2012
Clinical trials: new opportunities.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2012, Volume: 67, Issue:7

    Topics: Aging; Alzheimer Disease; Animals; Brain; Clinical Trials as Topic; Cognition Disorders; Guanfacine;

2012
Potential noradrenergic targets for cognitive enhancement in schizophrenia.
    CNS spectrums, 2004, Volume: 9, Issue:5

    Topics: Adrenergic alpha-Agonists; Atomoxetine Hydrochloride; Cognition Disorders; Guanfacine; Humans; Norep

2004
The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder.
    Archives of general psychiatry, 1996, Volume: 53, Issue:5

    Topics: Adrenergic alpha-Agonists; Animals; Attention Deficit Disorder with Hyperactivity; Clonidine; Cognit

1996

Trials

3 trials available for guanfacine and Cognition Disorders

ArticleYear
Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response.
    International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 2011, Volume: 82, Issue:1

    Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Brain; Brain Injuries; Brain Mapping; Cognition Disorde

2011
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.
    Biological psychiatry, 2007, May-15, Volume: 61, Issue:10

    Topics: Adrenergic alpha-Agonists; Adult; Cognition Disorders; Double-Blind Method; Female; Guanfacine; Huma

2007
Guanfacine treatment of cognitive impairment in schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001, Volume: 25, Issue:3

    Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe

2001
Guanfacine treatment of cognitive impairment in schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001, Volume: 25, Issue:3

    Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe

2001
Guanfacine treatment of cognitive impairment in schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001, Volume: 25, Issue:3

    Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe

2001
Guanfacine treatment of cognitive impairment in schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001, Volume: 25, Issue:3

    Topics: Adrenergic alpha-Agonists; Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Fe

2001

Other Studies

3 other studies available for guanfacine and Cognition Disorders

ArticleYear
Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive decline.
    Neuroscience, 2013, Dec-19, Volume: 254

    Topics: Adrenergic alpha-2 Receptor Agonists; Altitude Sickness; Animals; Cognition Disorders; Dendrites; Gu

2013
Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior.
    Translational psychiatry, 2015, May-19, Volume: 5

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Attention; Behavior, Animal; Carbon Radioisotopes; Co

2015
Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
    Journal of child and adolescent psychopharmacology, 2004,Summer, Volume: 14, Issue:2

    Topics: Adolescent; Adrenergic alpha-Agonists; Aging; Asperger Syndrome; Attention Deficit Disorder with Hyp

2004